184 related articles for article (PubMed ID: 7534919)
1. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
2. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients.
Rochon YP; Horoszewicz JS; Boynton AL; Holmes EH; Barren RJ; Erickson SJ; Kenny GM; Murphy GP
Prostate; 1994 Oct; 25(4):219-23. PubMed ID: 8084837
[TBL] [Abstract][Full Text] [Related]
3. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
[TBL] [Abstract][Full Text] [Related]
4. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
[TBL] [Abstract][Full Text] [Related]
5. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
6. Expression of the prostate-specific membrane antigen.
Israeli RS; Powell CT; Corr JG; Fair WR; Heston WD
Cancer Res; 1994 Apr; 54(7):1807-11. PubMed ID: 7511053
[TBL] [Abstract][Full Text] [Related]
7. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
[TBL] [Abstract][Full Text] [Related]
8. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.
Israeli RS; Miller WH; Su SL; Powell CT; Fair WR; Samadi DS; Huryk RF; DeBlasio A; Edwards ET; Wise GJ
Cancer Res; 1994 Dec; 54(24):6306-10. PubMed ID: 7527294
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Murphy G; Ragde H; Kenny G; Barren R; Erickson S; Tjoa B; Boynton A; Holmes E; Gilbaugh J; Douglas T
Anticancer Res; 1995; 15(4):1473-9. PubMed ID: 7544569
[TBL] [Abstract][Full Text] [Related]
11. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
Koutsilieris M; Lembessis P; Luu-The V; Sourla A
Clin Exp Metastasis; 1999; 17(10):823-30. PubMed ID: 11089880
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of an enzyme-linked immunoassay for the prostate: specific antigen utilizing two monoclonal antibodies.
Zundel D; Jarry H; Kestler D; Holzapfel G; Bartels H; Scheit KH; Wuttke W
Urol Res; 1990; 18(5):327-30. PubMed ID: 1701585
[TBL] [Abstract][Full Text] [Related]
13. Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
Okegawa T; Yoshioka J; Morita R; Nutahara K; Tsukada Y; Higashihara E
Int J Urol; 1998 Jul; 5(4):349-56. PubMed ID: 9712443
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto JT; Suffoletto BP; Berzin TM; Qiao CH; Lin S; Tong WP; May F; Mukherjee B; Heston WD
Clin Cancer Res; 1996 Sep; 2(9):1445-51. PubMed ID: 9816319
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Horoszewicz JS; Kawinski E; Murphy GP
Anticancer Res; 1987; 7(5B):927-35. PubMed ID: 2449118
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
[TBL] [Abstract][Full Text] [Related]
20. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
